Quarterly Activities/Appendix 4C Cash Flow Report
| Stock | BLS.ASX (BLS.ASX) |
|---|---|
| Release Time | 27 Jul 2026, 8:52 a.m. |
| Price Sensitive | Yes |
BLS Pharmaceuticals Reports Record FY26 Performance and Expansion
- Record quarterly revenue of $22.5 million, FY26 revenue at $74.98 million
- Record FY26 Adjusted EBITDA of $19 million
- Secured $50 million pharmaceutical supply agreement with ADREXpharma
- First international supply to Costa Rica
- Transitioned to BLS Pharmaceuticals Limited
BLS Pharmaceuticals Limited (ASX: BLS) reported record financial performance for the year ended 30 June 2026. The company delivered a quarterly revenue of $22.5 million, achieving a full-year revenue of $74.98 million at the top end of its guidance range. BLS also reported a record Adjusted EBITDA of $19 million for FY26, up 190% from the prior year. The company expanded its international presence by securing a $50 million supply agreement with ADREXpharma in Germany and entering the Costa Rican market. BLS completed its transition to BLS Pharmaceuticals Limited, reflecting its evolution into an international pharmaceutical manufacturing business. The company enters FY27 with a strengthened balance sheet and a larger international platform.
FY26 revenue $74.98 million, Adjusted EBITDA $19 million
BLS expects to continue international growth, ramp up the ADREXpharma agreement, and complete its GMP manufacturing facility in Scotland.